Author:
Gunelli R,Bercovich E,Nanni O,Ballardini M,Frassineti G L,Giovannini N,Fiori M,Pasquini E,Ulivi P,Pappagallo G L,Silvestrini R,Zoli W
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN (1991) A Phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491–498
2. Bartoletti R, Cai T, Gacci M, Giubilei G, Viggiani F, Santelli G, Repetti F, Nerozzi S, Ghezzi P, Sisani M, TUR (Toscana Urologia) Group (2005) Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase 2 prospective multicenter study. Urology 66: 726–731
3. Campodonico F, Canepa G, Capponi G, Bozzo L, Maffezzini M (2005) Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability. Anticancer Res 25: 2381–2384
4. Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WD, Dalbagni G (1999) Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res 5: 2629–2637
5. Dalbagni G, Russo P, Bochner B, Ben-Porat L, Sheinfeld J, Sogani P, Donat MS, Herr HW, Bajorin D (2006) Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24: 2729–2734
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献